Optical integrating balloon device for photodynamic therapy

Dwyer, Peter; White, W. Matthew; Fabian, Richard L.; Anderson, R. R.

doi:10.1002/(sici)1096-9101(2000)26:1<58::aid-lsm9>3.0.co;2-v

Cited by 24 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several groups have now developed light delivery devices to achieve uniform output illumination. It was concluded that those new devices can be used clinically to deliver light to the uterine cavity (166,167). Further studies are required to determine the safety of this technique for nontarget tissues that bind the photosensitizer, and whether endometrial regeneration will be prevented.…”

Section: Methodsmentioning

confidence: 99%

Menorrhagia: an update

Oehler

Rees

2003

Acta Obstet Gynecol Scand

140

View full text Add to dashboard Cite

Menorrhagia is defined as a 'complaint of heavy cyclical menstrual bleeding occurring over several consecutive cycles'. Objectively it is a total menstrual blood loss equal to or greater than 80 ml per menstruation. It is estimated that approximately 30% of women complain of menorrhagia. Excessive bleeding is the main presenting complaint in women referred to gynecologists and it accounts for two-thirds of all hysterectomies, and most of endoscopic endometrial destructive surgery. Thus, menorrhagia is an important healthcare problem. Its etiology, investigation, medical and surgical management are described. In approximately 50% of cases of menorrhagia no pathology is found at hysterectomy. Abnormal levels of prostaglandins or the fibrinolytic system in the endometrium have been implicated. Effective medical treatments suitable for long-term use include intrauterine progestogens, antifibrinolytic agents (tranexamic acid) and nonsteroidal anti-inflammatory agents (mefenamic acid). Over the past decade there has been increasing use of endometrial destructive techniques as an alternative to hysterectomy. Their further refinement and the advent of fibroid embolization has increased the options available to women.

show abstract

Section: Methodsmentioning

confidence: 99%

Menorrhagia: an update

Oehler

Rees

2003

Acta Obstet Gynecol Scand

140

View full text Add to dashboard Cite

show abstract

“…In this context, a deformable balloon is expected to meet this requirement. Several devices have been designed for this purpose in the past, such as an inflatable balloon with different light sources [18][19][20][21][22] , an optical fiber coupled to a reflector, or a laser light source coupled to the surgical microscope, enabling a step by step illumination 23 . Moseley et al described the only clinical study using 5-ALA as a precursor for the treatment of GBM with PDT 20,21 .…”

Section: Imentioning

confidence: 99%

INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial

et al. 2018

View full text Add to dashboard Cite

This INDYGO trial assesses the feasibility of intraoperative 5-aminolevulinic acid PDT, a novel seamless approach to treat GBM. The technology is easily embeddable within the reference treatment at a low-incremental cost. The safety of this new treatment modality is a preliminary requirement before a multicenter randomized clinical trial can be further conducted to assess local control improvement by treating infiltrating and nonresected GBM cells.

show abstract

“…Generally, however, radial/cylindrical diffusers offer an interesting way to deliver intravascular illumination for the treatment of acute coronary syndromes and regional atherosclerosis, especially for plaque stabilization, as opposed to plaque ablation. As these 10‐ to 40‐mm‐long cylindrical light‐emitting distributors are frequently introduced in the treated vessel through a catheter, caution must be exercised to ensure that the illumination profile of the diffuser is not modified by the catheter's material . Similar caution must be exercised when the light distributor is centered within the vessel's lumen with an inflatable balloon.…”

Section: Light Source and Light Diffusersmentioning

confidence: 99%

Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?

Jain

Zellweger

Wagnières

et al. 2017

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Summary Acute coronary syndrome is a life‐threatening condition of utmost clinical importance, which, despite recent progress in the field, is still associated with high morbidity and mortality. Acute coronary syndrome results from a rupture or erosion of vulnerable atherosclerotic plaque with secondary platelet activation and thrombus formation, which leads to partial or complete luminal obstruction of a coronary artery. During the last decade, scientific evidence demonstrated that when an acute coronary event occurs, several nonculprit plaques are in a “vulnerable” state. Among the promising approaches, several investigations provided evidence of photodynamic therapy (PDT)‐induced stabilization and regression of atherosclerotic plaque. Significant development of PDT strategies improved its therapeutic outcome. This review addresses PDT's pertinence and major problems/challenges toward its translation to a clinical reality.

show abstract

Optical integrating balloon device for photodynamic therapy

Cited by 24 publications

References 19 publications

Menorrhagia: an update

Menorrhagia: an update

INtraoperative photoDYnamic Therapy for GliOblastomas (INDYGO): Study Protocol for a Phase I Clinical Trial

Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?

Contact Info

Product

Resources

About